Targeting the PI3K/AKT Pathway Overcomes Enzalutamide Resistance by Inhibiting Induction of the Glucocorticoid ReceptorRemi Adelaiye‐Ogala, David James VanderWeele, Brian J. Capaldo et al.|Molecular Cancer Therapeutics|2020Cited by 55
Data from Targeting the PI3K/AKT Pathway Overcomes Enzalutamide Resistance by Inhibiting Induction of the Glucocorticoid ReceptorRemi Adelaiye‐Ogala, David James VanderWeele, Berkley E. Gryder et al.|Unknown|2023Cited by 0
Data from Targeting the PI3K/AKT Pathway Overcomes Enzalutamide Resistance by Inhibiting Induction of the Glucocorticoid ReceptorRemi Adelaiye‐Ogala, David James VanderWeele, Berkley E. Gryder et al.|Unknown|2023Cited by 0
Supplementary Table 1 and Figure S1- S8 from Targeting the PI3K/AKT Pathway Overcomes Enzalutamide Resistance by Inhibiting Induction of the Glucocorticoid ReceptorRemi Adelaiye‐Ogala, David James VanderWeele, Berkley E. Gryder et al.|Unknown|2023Cited by 0
Supplementary Table 1 and Figure S1- S8 from Targeting the PI3K/AKT Pathway Overcomes Enzalutamide Resistance by Inhibiting Induction of the Glucocorticoid ReceptorRemi Adelaiye‐Ogala, David James VanderWeele, Berkley E. Gryder et al.|Unknown|2023Cited by 0